Enhancing myocardial plasmid expression by retrograde coronary venous delivery

Eyas Al Shaykh Youssef, Ping Zhang, Pamela I. Rogers, Patrice Tremble, Joe Rokovich, Brian H. Johnstone, Keith L. March, Dongming Hou

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Myocardial delivery of genes holds great promise for treating many heart diseases; however, the optimal delivery technique, which maximizes safety and efficacy, has not been established. Two delivery techniques were evaluated in swine; percutaneous retrograde coronary venous delivery (RCVD) and direct intramyocardial injection (IM). RCVD was performed in the anterior interventricular vein (AIV) with an end-hole occlusion balloon catheter. The plasmid gWiz, encoding β-galactosidase (10 ml; 1 mg/ml), was injected using either manual high pressure (HP-RCVD; n = 5) or pressure wire-guided low pressure (LP-RCVD; n = 4). For the IM group (n = 4), β-Gal plasmid (5 mg/ml) was injected at 10 sites (200 μl/site) in the anterior left ventricular wall. Animals were euthanized after 5 days. The percentage of β-Gal expressing cells in the delivered region was higher in the HP-RCVD (0.26% ± 0.05%) than the LP-RCVD (0.05% = 0.03%; P = 0.07) and IM groups (0.02% ± 0.01%; P = 0.01). Myocardium from the HP-RCVD group contained 7- and 17-fold higher levels of β-Gal activity than either LP-RCVD and IM groups, respectively (P = 0.05 for both). The results of this study confirm the safety and efficacy of RCVD for myocardial gene delivery.

Original languageEnglish
Pages (from-to)528-534
Number of pages7
JournalCatheterization and Cardiovascular Interventions
Volume65
Issue number4
DOIs
StatePublished - Aug 2005

Fingerprint

Plasmids
Injections
Pressure
Galactosidases
Safety
Balloon Occlusion
Genes
Veins
Heart Diseases
Myocardium
Swine
Catheters

Keywords

  • Coronary venous
  • Gene delivery
  • Myocardium
  • Plasmid

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Youssef, E. A. S., Zhang, P., Rogers, P. I., Tremble, P., Rokovich, J., Johnstone, B. H., ... Hou, D. (2005). Enhancing myocardial plasmid expression by retrograde coronary venous delivery. Catheterization and Cardiovascular Interventions, 65(4), 528-534. https://doi.org/10.1002/ccd.20450

Enhancing myocardial plasmid expression by retrograde coronary venous delivery. / Youssef, Eyas Al Shaykh; Zhang, Ping; Rogers, Pamela I.; Tremble, Patrice; Rokovich, Joe; Johnstone, Brian H.; March, Keith L.; Hou, Dongming.

In: Catheterization and Cardiovascular Interventions, Vol. 65, No. 4, 08.2005, p. 528-534.

Research output: Contribution to journalArticle

Youssef, EAS, Zhang, P, Rogers, PI, Tremble, P, Rokovich, J, Johnstone, BH, March, KL & Hou, D 2005, 'Enhancing myocardial plasmid expression by retrograde coronary venous delivery', Catheterization and Cardiovascular Interventions, vol. 65, no. 4, pp. 528-534. https://doi.org/10.1002/ccd.20450
Youssef, Eyas Al Shaykh ; Zhang, Ping ; Rogers, Pamela I. ; Tremble, Patrice ; Rokovich, Joe ; Johnstone, Brian H. ; March, Keith L. ; Hou, Dongming. / Enhancing myocardial plasmid expression by retrograde coronary venous delivery. In: Catheterization and Cardiovascular Interventions. 2005 ; Vol. 65, No. 4. pp. 528-534.
@article{b25cc7fe207f4ccd8c54ba7d7d9a74ac,
title = "Enhancing myocardial plasmid expression by retrograde coronary venous delivery",
abstract = "Myocardial delivery of genes holds great promise for treating many heart diseases; however, the optimal delivery technique, which maximizes safety and efficacy, has not been established. Two delivery techniques were evaluated in swine; percutaneous retrograde coronary venous delivery (RCVD) and direct intramyocardial injection (IM). RCVD was performed in the anterior interventricular vein (AIV) with an end-hole occlusion balloon catheter. The plasmid gWiz, encoding β-galactosidase (10 ml; 1 mg/ml), was injected using either manual high pressure (HP-RCVD; n = 5) or pressure wire-guided low pressure (LP-RCVD; n = 4). For the IM group (n = 4), β-Gal plasmid (5 mg/ml) was injected at 10 sites (200 μl/site) in the anterior left ventricular wall. Animals were euthanized after 5 days. The percentage of β-Gal expressing cells in the delivered region was higher in the HP-RCVD (0.26{\%} ± 0.05{\%}) than the LP-RCVD (0.05{\%} = 0.03{\%}; P = 0.07) and IM groups (0.02{\%} ± 0.01{\%}; P = 0.01). Myocardium from the HP-RCVD group contained 7- and 17-fold higher levels of β-Gal activity than either LP-RCVD and IM groups, respectively (P = 0.05 for both). The results of this study confirm the safety and efficacy of RCVD for myocardial gene delivery.",
keywords = "Coronary venous, Gene delivery, Myocardium, Plasmid",
author = "Youssef, {Eyas Al Shaykh} and Ping Zhang and Rogers, {Pamela I.} and Patrice Tremble and Joe Rokovich and Johnstone, {Brian H.} and March, {Keith L.} and Dongming Hou",
year = "2005",
month = "8",
doi = "10.1002/ccd.20450",
language = "English",
volume = "65",
pages = "528--534",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Enhancing myocardial plasmid expression by retrograde coronary venous delivery

AU - Youssef, Eyas Al Shaykh

AU - Zhang, Ping

AU - Rogers, Pamela I.

AU - Tremble, Patrice

AU - Rokovich, Joe

AU - Johnstone, Brian H.

AU - March, Keith L.

AU - Hou, Dongming

PY - 2005/8

Y1 - 2005/8

N2 - Myocardial delivery of genes holds great promise for treating many heart diseases; however, the optimal delivery technique, which maximizes safety and efficacy, has not been established. Two delivery techniques were evaluated in swine; percutaneous retrograde coronary venous delivery (RCVD) and direct intramyocardial injection (IM). RCVD was performed in the anterior interventricular vein (AIV) with an end-hole occlusion balloon catheter. The plasmid gWiz, encoding β-galactosidase (10 ml; 1 mg/ml), was injected using either manual high pressure (HP-RCVD; n = 5) or pressure wire-guided low pressure (LP-RCVD; n = 4). For the IM group (n = 4), β-Gal plasmid (5 mg/ml) was injected at 10 sites (200 μl/site) in the anterior left ventricular wall. Animals were euthanized after 5 days. The percentage of β-Gal expressing cells in the delivered region was higher in the HP-RCVD (0.26% ± 0.05%) than the LP-RCVD (0.05% = 0.03%; P = 0.07) and IM groups (0.02% ± 0.01%; P = 0.01). Myocardium from the HP-RCVD group contained 7- and 17-fold higher levels of β-Gal activity than either LP-RCVD and IM groups, respectively (P = 0.05 for both). The results of this study confirm the safety and efficacy of RCVD for myocardial gene delivery.

AB - Myocardial delivery of genes holds great promise for treating many heart diseases; however, the optimal delivery technique, which maximizes safety and efficacy, has not been established. Two delivery techniques were evaluated in swine; percutaneous retrograde coronary venous delivery (RCVD) and direct intramyocardial injection (IM). RCVD was performed in the anterior interventricular vein (AIV) with an end-hole occlusion balloon catheter. The plasmid gWiz, encoding β-galactosidase (10 ml; 1 mg/ml), was injected using either manual high pressure (HP-RCVD; n = 5) or pressure wire-guided low pressure (LP-RCVD; n = 4). For the IM group (n = 4), β-Gal plasmid (5 mg/ml) was injected at 10 sites (200 μl/site) in the anterior left ventricular wall. Animals were euthanized after 5 days. The percentage of β-Gal expressing cells in the delivered region was higher in the HP-RCVD (0.26% ± 0.05%) than the LP-RCVD (0.05% = 0.03%; P = 0.07) and IM groups (0.02% ± 0.01%; P = 0.01). Myocardium from the HP-RCVD group contained 7- and 17-fold higher levels of β-Gal activity than either LP-RCVD and IM groups, respectively (P = 0.05 for both). The results of this study confirm the safety and efficacy of RCVD for myocardial gene delivery.

KW - Coronary venous

KW - Gene delivery

KW - Myocardium

KW - Plasmid

UR - http://www.scopus.com/inward/record.url?scp=23044478616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044478616&partnerID=8YFLogxK

U2 - 10.1002/ccd.20450

DO - 10.1002/ccd.20450

M3 - Article

VL - 65

SP - 528

EP - 534

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 4

ER -